Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-15
2007-05-15
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
09547825
ABSTRACT:
The invention, at least in part, is directed to methods for enhancing delivery of therapeutic agents, such as macromolecules and drugs, into the interior of tissues, such as solid tissues or tumors. The method initially uses an apoptosis inducing agent, such as paclitaxel, in doses which create channels within the tissues, and enhance the penetration of therapeutic agents to the interior of the tissue. Current methods of treating tissues are often not effective because the therapeutic agents are not delivered to the interior of the tissue. By using the methods and the compositions of the current invention, therapeutic agents can be delivered to the interior of the tissue.
REFERENCES:
patent: 5710134 (1998-01-01), Bosslet et al.
patent: WO 98/32440 (1998-07-01), None
Zhang, et al., Urology, 1998, 52(5):925-931.
Nielsen, et al, , 1998, Clin Cancer Res, 4(4):835-46.
Sharma, et al 1996, Oncol Res 8(7-8):281-6.
Gan, et al., 1996, Cancer Res, 56:2086-93.
Nicholson, et al. 1997, Eur J Cancer, 33(8):1291-1298.
Kerr, 1994, Cancer, 73(8):2013-26.
Gehl et al (Semin Oncol Dec. 1996;23, 6 Suppl 15: 35-8).
Hortobagyi et al (Semin Oncol, Feb. 24, 1997, 1 Suppl 3, S4-7.
Merkle et al (Dec. 1998, Gene Therapy, vol. 5, pp. 1631-1641, abstract only).
Au JL, et al. “Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention”.Cancer Res. May 15, 1998;58(10):2141-8.
Baguley BC, et al. “Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumors”.Clin Exp Pharmacol Physiol. Nov. 1995;22(11):825-8.
Bhalla K, et al. “Characterization of a human myeloid leukemia cell line highly resistant to taxol.”Leukemia. Mar. 1994;8(3):465-75.
Chen CT, et al. “Pharmacodynamics of doxorubicin in human prostate tumors.”Clin CancerRes. Feb. 1998;4(2):277-82.
Derry WB, et al. “Substoichiometric binding of taxol suppresses microtubule dynamics”.Biochemistry. Feb. 21, 1995;34(7):2203-11.
Durad RE. “Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage?”Cancer Chemother Pharmacol. 1990;26(3):198-204.
Erlanson M, et al. “Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids.” Cancer Chemother Pharmacol. 1992;29(5):343-53.
Gan Y, et al. “Pharmacodynamics of taxol in human head and neck tumors”.Cancer Res. May 1, 1996;56(9):2086-93.
Gold R, et al. “Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.”Lab Invest. Aug. 1994;71(2):219-25.
Jain RK. “Delivery of molecular medicine to solid tumors”.Science. Feb. 23, 1996;271(5252):1079-80.
Jekunen AP, et al. “Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro”.Br J Cancer. Feb. 1994;69(2):299-306.
Jordan MA, et al. “Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations”.Proc Natl Acad Sci U S A. Oct. 15, 1993;90(20):9552-6.
Jordan MA, et al. “Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.”Cancer Res. Feb. 15, 1996;56(4):816-25.
Kang et al. “A kinetic model for taxol accumulation in human cancer cells: In vivo extrapolation” 1997Proc Am Assoc Cancer Res38:604.
Kerr JF, et al. “Apoptosis. Its significance in cancer and cancer therapy.”Cancer. Apr. 15, 1994;73(8):2013-26.
Kleinman H et al. “Role of Membrane and Laminin in Metastases and Tumor Growth:” 1990Proc Am Assoc Cancer Res31:490-491.
Kuh HJ, et al. “Determinants of paclitaxel penetration and accumulation in human solid tumor.”J Pharmacol Exp Ther. Aug. 1999;290(2):871-80.
Lesser GJ, et al. “The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study”.Cancer Chemother Pharmacol. 1995;37(1-2):173-8.
Lopes NM, et al. “Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines”.Cancer Chemother Pharmacol. 1993;32(3):235-42.
Parness J, et al. “Taxol binds to polymerized tubulin in vitro”.J. Cell Biol. Nov. 1981;91(2 Pt 1):479-87.
Manfredi JJ, et al. “Taxol binds to cellular microtubules”.J Cell Biol. Sep. 1982;94(3):688-96.
Markman M. “Intraperitoneal therapy of ovarian cancer.”Semin Oncol. Jun. 1998;25(3):356-60.
Nativ O, et al. “Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies”.Int J Cancer. Jan. 27, 1997;70(3):297-301.
Nicholson KM, et al. “Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids.”Eur J Cancer. Jul. 1997;33(8):1291-8.
Pavelic ZP, et al. “Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues”Arch Otolaryngol Head Neck Surg. Jul. 1993;119(7):753-7.
Ringel I, et al. “Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium”.J Pharmacol Exp Ther. Aug. 1987;242(2):692-8.
Saunders DE, et al. “Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells”. Int 3 Cancer. Jan. 17, 1997;70(2):214-20.
Schinkel AH, et al. “Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies”.Cancer Res. May 15, 1991;51(10):2625-35.
Smith DC. “Chemotherapy for hormone refractory prostate cancer”.Urol Clin North Am. May 1999;26(2):323-31.
Song D, et al. “Bladder tissue pharmacokinetics of intravesical taxol”.Cancer Chemother Pharmacol. 1997;40(4):285-92.
Speicher LA, et al. “P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine”.J. Natl Cancer Inst. May 4, 1994;86(9):688-94.
Toth K, et al. “New immunohistochemical “sandwich” staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues”.Am J Pathol. Feb. 1994;144(2):227-36.
Umezawa, K., (1999), Japanese Pub. No. 11322620, “Transcription factor NF kappa B activation inhibitor—comprises coniferin derivative which acts as an apoptosis activator”, (Abstract).
Takashi, H., (1998), Japanese Pub. No. 11269065, “Controlling agent for apoptosis resistance of cancer cells”, (Abstract).
Ariyoshi, Y. et al., “Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay.” Oral Oncol., 39:701-707 (2003).
Au, J. L.-S., et al., “Histocultures of patient head and neck tumors for pharmacodynamics studies.” Pharm. Res., 10:1493-1499 (1993).
Au, J. L.-S., et al., “Pharmacologic effects of Paclitaxel in human bladder tumors.” Cancer Chemother.Pharmacol., 41:69-74 (1997).
Au, J. L.-S., et al., “Pharmacodynamics of immediate and delayed effects of Paclitaxel: Role of slow apoptosis and intracellular drug retention.” Cancer Res., 58:2141-2148 (1998).
Au, J. L.-S., et al., “Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.” J. Natl. Cancer Inst., 93:597-604 (2001).
Au, J. L.-S., et al., “Determinants of drug delivery and transport to solid tumors.” J. Control. Release, 74:31-46 (2001).
Au, J. L.-S., et al., Clinical aspects of drug delivery to tumors. J. Control. Release, 78:81-95, 2002.
Chang, A.Y., et al., “Weekly paclitaxel in advanced non-small cell lung cancer.” Semin.Oncol., 28:10-13 (2001).
Chen, C.-T., et al., “Differential time dependency of antiproliferative and apoptotic effects of Taxol in human prostate tumors.” Urol.Oncol., 3:11-17 (1997).
Chen, C.-T., et al., “Pharmacodynamics of Doxorubicin in hu
Au Jessie L.-S.
Wientjes Guillaume
Mueller Smith & Matto
Yu Misook
LandOfFree
Methods and compositions for enhancing delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for enhancing delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for enhancing delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745695